Hyperthyroidism in Graves Disease When Thionamide Therapy Has Not Normalized Thyroid Function

Clinical Scenario

Graves disease is an autoimmune disorder in which thyroid-stimulating antibodies activate TSH receptors, triggering excess thyroid hormone synthesis. It is the most common cause of hyperthyroidism in the United States.

Previous Treatment — Goals Not Reached

Thionamide therapy was the initial line of treatment, with the goal of normalizing free T4 and total T3, reassessed four weeks after starting the medication. When those targets are not achieved, escalation to a definitive approach is required.

Next Step — Partial Overview

Definitive ablation of the thyroid is the established approach at this stage. Radioactive iodine (I-131) is the most commonly used modality in this setting. The complete protocol details how the appropriate option is selected and specifies the thyroid function markers used to assess resolution after ablation.

Instant Access to Structured Evidence-Based Regimens

References

Graves disease, the most common cause of hyperthyroidism in the United States, is an autoimmune disorder in which thyroid-stimulating antibodies activate thyroid-stimulating hormone (TSH) receptors, triggering thyroid hormone synthesis.

Radioactive iodine ablation of the thyroid gland is the most common treatment of Graves disease in the United States.

Free T4 and total T3 should be measured four to eight weeks after ablation; if hyperthyroidism persists, these indices should be monitored every four to six weeks and thyroid hormone replacement started in the early stages of hypothyroidism.

View source ↗